Lipocine (LPCN) Competitors $4.91 +0.20 (+4.25%) (As of 03:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LPCN vs. TNXP, LTRN, CEMI, LPTX, CLLS, AVTX, IPSC, MNPR, COYA, and TLSAShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Tonix Pharmaceuticals (TNXP), Lantern Pharma (LTRN), Chembio Diagnostics (CEMI), Leap Therapeutics (LPTX), Cellectis (CLLS), Avalo Therapeutics (AVTX), Century Therapeutics (IPSC), Monopar Therapeutics (MNPR), Coya Therapeutics (COYA), and Tiziana Life Sciences (TLSA). These companies are all part of the "medical" sector. Lipocine vs. Tonix Pharmaceuticals Lantern Pharma Chembio Diagnostics Leap Therapeutics Cellectis Avalo Therapeutics Century Therapeutics Monopar Therapeutics Coya Therapeutics Tiziana Life Sciences Tonix Pharmaceuticals (NASDAQ:TNXP) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Do insiders and institutionals hold more shares of TNXP or LPCN? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 6.1% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer TNXP or LPCN? Tonix Pharmaceuticals currently has a consensus target price of $53.50, indicating a potential upside of 26,437.70%. Lipocine has a consensus target price of $10.00, indicating a potential upside of 103.67%. Given Tonix Pharmaceuticals' higher possible upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor TNXP or LPCN? Lipocine received 7 more outperform votes than Tonix Pharmaceuticals when rated by MarketBeat users. Likewise, 69.82% of users gave Lipocine an outperform vote while only 61.82% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34061.82% Underperform Votes21038.18% LipocineOutperform Votes34769.82% Underperform Votes15030.18% Is TNXP or LPCN more profitable? Lipocine has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Lipocine's return on equity of -19.17% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Lipocine N/A -19.17%-17.60% Which has more risk and volatility, TNXP or LPCN? Tonix Pharmaceuticals has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Does the media favor TNXP or LPCN? In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Lipocine. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 2 mentions for Lipocine. Tonix Pharmaceuticals' average media sentiment score of 0.04 beat Lipocine's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, TNXP or LPCN? Lipocine has lower revenue, but higher earnings than Tonix Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$7.77M3.56-$116.66M-$52.740.00Lipocine$500K52.54-$16.35M-$0.76-6.46 SummaryLipocine beats Tonix Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.27M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-6.465.5695.6214.26Price / Sales52.54371.591,217.1987.73Price / CashN/A52.5939.5936.27Price / Book1.3810.236.946.36Net Income-$16.35M$153.22M$118.89M$225.56M7 Day Performance-5.76%-1.36%-1.33%-0.10%1 Month Performance-11.69%-6.81%-3.17%2.02%1 Year Performance95.62%32.27%32.49%27.87% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine2.0601 of 5 stars$4.91+4.2%$10.00+103.7%+96.3%$26.27M$500,000.00-6.4610TNXPTonix Pharmaceuticals2.9424 of 5 stars$0.20+6.1%$53.50+26,437.7%-98.8%$27.67M$7.77M0.00103Analyst ForecastGap DownHigh Trading VolumeLTRNLantern Pharma1.0538 of 5 stars$2.91-1.0%N/A-27.0%$31.37MN/A0.0020Positive NewsCEMIChembio DiagnosticsN/A$0.46flatN/A+0.0%$16.71M$48.34M-0.38337Analyst ForecastLPTXLeap Therapeutics2.4038 of 5 stars$2.58-0.4%$7.50+190.7%+25.1%$66.05M$1.50M0.0040Positive NewsCLLSCellectis2.8825 of 5 stars$1.89-1.0%$7.00+270.4%-38.4%$105.05M$9.19M0.00290Analyst ForecastAVTXAvalo Therapeutics2.3663 of 5 stars$10.07-7.6%N/A-47.4%$104.63M$1.92M0.0040Positive NewsIPSCCentury Therapeutics1.5802 of 5 stars$1.23-2.8%$11.60+846.9%-11.9%$104.16M$2.23M0.00170MNPRMonopar Therapeutics3.5896 of 5 stars$19.60+3.2%$27.33+39.5%+1,213.5%$103.49MN/A0.0010COYACoya Therapeutics3.0537 of 5 stars$6.17+2.3%$16.67+170.1%+10.6%$103.10M$6M0.006TLSATiziana Life Sciences0.5465 of 5 stars$0.97-3.0%N/A+75.4%$102.20MN/A0.008Positive News Related Companies and Tools Related Companies TNXP Alternatives LTRN Alternatives CEMI Alternatives LPTX Alternatives CLLS Alternatives AVTX Alternatives IPSC Alternatives MNPR Alternatives COYA Alternatives TLSA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LPCN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
